Patient Care banner

Penn Thyroid


PENN Thyroid Center

Over 12 million Americans have thyroid nodules that require medical evaluation. In addition, the annual incidence of thyroid cancer is rapidly rising and its rate of increase outpaces that of all other malignancies. Last year, over 37,000 Americans were diagnosed with thyroid cancer, which afflicts women three times more than men. Southeastern Pennsylvania and southern New Jersey have among the highest incidence rates for thyroid cancer in the United States. Alarmingly, the number of patients with thyroid nodules and the mortality rate from thyroid cancer continue to increase. This highlights the need for our PENN Thyroid Center that specializes in the diagnosis and treatment of thyroid cancer, that translates exciting new scientific discoveries into new treatments for patients, and that encourages and trains the next generation of health professionals to make a difference in thyroid disease.

PENN Thyroid Center:
The PENN Thyroid Center provides comprehensive multidisciplinary clinical care of patients with thyroid nodules and thyroid cancer. This requires the dedication and coordination of outstanding physicians in many different specialty disciplines caring for these patients, including: Endocrinology, Radiology, Pathology, Surgery, Nuclear Medicine, Medical Oncology, Radiation Oncology.

Comprehensive services of the PENN Thyroid Center include clinical evaluation of patients with thyroid nodules, ultrasound-guided fine needle aspiration for cytological diagnosis, surgery, staging, 131I treatment, external beam radiation therapy, long term follow-up, and, in conjunction with the Abramson Cancer Center, novel therapies for patients with aggressive thyroid cancer. This interdisciplinary structure of the PENN Thyroid Center is unique not only in the Delaware Valley, but in the United States.

The PENN Thyroid Center also coordinates translational and patient-oriented research, providing innovative partnership with basic science discovery. Exciting discoveries in the molecular pathology of thyroid cancer are leading to the potential for personalized and targeted cancer therapies and coordinated evaluation that the PENN Thyroid Center will be uniquely suited to provide.